Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report.

Lorenzo Esposito, Ilaria Cappuccio, Fabrizio Pane, Alessandro Severino

Abstract readCase Reports

In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lorenzo EspositoHematology Department, Federico II University of Naples, Naples, Italy. lorenzo.esposito1981@gmail.com.

Ilaria CappuccioHematology Department, Federico II University of Naples, Naples, Italy.

Fabrizio PaneHematology Department, Federico II University of Naples, Naples, Italy.

Alessandro SeverinoHematology Department, Federico II University of Naples, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marginal zone lymphomas (MZL) are indolent lymphomas that may undergo transformation into aggressive lymphomas, most frequently diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine (LONCA) is an antibody-drug conjugate used in the treatment of relapsed/refractory large B-cell lymphomas. Here we present the clinical case of a patient with nodal transformed DLBCL and concomitant bone marrow involvement by indolent lymphoma successfully treated with LONCA. However the therapy was discontinued after six cycles as the patient developed treatment-related bone marrow aplasia. This case raises concerns about prolonged hematologic toxicity of LONCA, particularly in patients with pre-existing marrow involvement while highlights the potential of this drug to induce deep and durable response, even after limited exposure.

Indexed as

Bone MarrowImmunoconjugatesLymphoma, B-Cell, Marginal ZoneAntibodies, Monoclonal, HumanizedBenzodiazepinesCytopeniaHumansPathologic Complete ResponseRemission InductionAntibodies, Monoclonal, HumanizedBenzodiazepinesImmunoconjugatesloncastuximab tesirineBone marrow involvementHistological transformationLoncaMZLPancytopenia

Identifiers

PMID42113059

DOI10.1007/s00277-026-07050-9

PMCPMC13328221

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.